Logo image of XTNT

XTANT MEDICAL HOLDINGS INC (XTNT) Stock Price, Forecast & Analysis

USA - NYSEARCA:XTNT - US98420P3082 - Common Stock

0.76 USD
+0.01 (+1.33%)
Last: 11/10/2025, 2:28:40 PM

XTNT Key Statistics, Chart & Performance

Key Statistics
Market Cap106.40M
Revenue(TTM)127.77M
Net Income(TTM)-4.58M
Shares140.00M
Float119.10M
52 Week High0.95
52 Week Low0.33
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.04
PEN/A
Fwd PE149.02
Earnings (Next)11-11 2025-11-11/bmo
IPO2010-06-30
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Supplies


XTNT short term performance overview.The bars show the price performance of XTNT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40

XTNT long term performance overview.The bars show the price performance of XTNT in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40

The current stock price of XTNT is 0.76 USD. In the past month the price increased by 5.17%. In the past year, price increased by 43.22%.

XTANT MEDICAL HOLDINGS INC / XTNT Daily stock chart

XTNT Latest News, Press Relases and Analysis

XTNT Competitors/Peers

The largest stocks on the US markets in the "Health Care Supplies" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
COO COOPER COS INC/THE17.5414.02B
SOLV SOLVENTUM CORP12.0312.39B
ALGN ALIGN TECHNOLOGY INC14.149.91B
MMSI MERIT MEDICAL SYSTEMS INC23.675.21B
LNTH LANTHEUS HOLDINGS INC8.533.46B
ICUI ICU MEDICAL INC17.783.49B
HAE HAEMONETICS CORP/MASS14.783.42B
XRAY DENTSPLY SIRONA INC7.022.21B
UFPT UFP TECHNOLOGIES INC27.231.81B
NEOG NEOGEN CORP21.271.39B
STAA STAAR SURGICAL CON/A1.33B
EMBC EMBECTA CORP4.71804.83M

About XTNT

Company Profile

XTNT logo image Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. The company is headquartered in Belgrade Montana, Montana and currently employs 217 full-time employees. The company went IPO on 2010-06-30. The firm is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoVive, OsteoFactor, line of 3Demin products, as well as other allografts. The company offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical products, Thoracolumbar products, Sacroiliac Joint products, Interbody products and Interlaminar Stabilization products.

Company Info

XTANT MEDICAL HOLDINGS INC

664 Cruiser Lane

Belgrade Montana MONTANA 59714 US

CEO: Sean E. Browne

Employees: 225

XTNT Company Website

XTNT Investor Relations

Phone: 14063880480

XTANT MEDICAL HOLDINGS INC / XTNT FAQ

What does XTNT do?

Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. The company is headquartered in Belgrade Montana, Montana and currently employs 217 full-time employees. The company went IPO on 2010-06-30. The firm is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoVive, OsteoFactor, line of 3Demin products, as well as other allografts. The company offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical products, Thoracolumbar products, Sacroiliac Joint products, Interbody products and Interlaminar Stabilization products.


What is the stock price of XTANT MEDICAL HOLDINGS INC today?

The current stock price of XTNT is 0.76 USD. The price increased by 1.33% in the last trading session.


Does XTANT MEDICAL HOLDINGS INC pay dividends?

XTNT does not pay a dividend.


What is the ChartMill rating of XTANT MEDICAL HOLDINGS INC stock?

XTNT has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Can you provide the market cap for XTANT MEDICAL HOLDINGS INC?

XTANT MEDICAL HOLDINGS INC (XTNT) has a market capitalization of 106.40M USD. This makes XTNT a Micro Cap stock.


When does XTANT MEDICAL HOLDINGS INC (XTNT) report earnings?

XTANT MEDICAL HOLDINGS INC (XTNT) will report earnings on 2025-11-11, before the market open.


What is the ownership structure of XTANT MEDICAL HOLDINGS INC (XTNT)?

You can find the ownership structure of XTANT MEDICAL HOLDINGS INC (XTNT) on the Ownership tab.


XTNT Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to XTNT. When comparing the yearly performance of all stocks, XTNT is one of the better performing stocks in the market, outperforming 89.27% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

XTNT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to XTNT. XTNT may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

XTNT Financial Highlights

Over the last trailing twelve months XTNT reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS decreased by -100% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -4.43%
ROE -9.44%
Debt/Equity 0.46
Chartmill High Growth Momentum
EPS Q2Q%166.67%
Sales Q2Q%18.26%
EPS 1Y (TTM)-100%
Revenue 1Y (TTM)15.16%

XTNT Forecast & Estimates

8 analysts have analysed XTNT and the average price target is 1.79 USD. This implies a price increase of 134.87% is expected in the next year compared to the current price of 0.76.

For the next year, analysts expect an EPS growth of 108.5% and a revenue growth 10.6% for XTNT


Analysts
Analysts85
Price Target1.79 (135.53%)
EPS Next Y108.5%
Revenue Next Year10.6%

XTNT Ownership

Ownership
Inst Owners57.12%
Ins Owners14.93%
Short Float %0.09%
Short Ratio0.67